Roivant Sciences Q2 2025 Earnings Report
Key Takeaways
Roivant reported a net revenue of $4.475 million. The company's R&D expenses were $143.1 million, and G&A expenses were $202.9 million. Roivant reported consolidated cash, cash equivalents and marketable securities of approximately $5.4 billion at September 30, 2024. Roivant continued to return capital through share repurchases with $106M purchased for the quarter.
Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-in-indication efficacy sustained to one year.
IMVT-1402 cleared five Investigational New Drug (IND) applications across a range of therapeutic areas and FDA divisions.
Batoclimab proof of concept data in Graves’ disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition.
Mosliciguat Phase 1b data in pulmonary hypertension (PH) patients demonstrated some of the highest pulmonary vascular resistance (PVR) reductions (~38%) in PH trials to date.
Roivant Sciences
Roivant Sciences
Forward Guidance
Roivant anticipates several major milestones in the coming months, including data readouts and trial initiations.
Positive Outlook
- Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the fourth quarter of calendar year 2024.
- Immunovant plans to have initiated 4-5 potentially registrational programs by March 31, 2025, and plans to have initiated studies in a total of 10 indications by March 31, 2026, for IMVT-1402.
- Immunovant expects to initiate potentially registrational trials in Graves’ Disease and difficult-to-treat rheumatoid arthritis by December 31, 2024 and March 31, 2025 respectively.
- Topline data from the batoclimab trial in MG is expected by March 31, 2025.
- Priovant plans to report topline data from the ongoing Phase 3 trial of brepocitinib in DM in the second half of calendar year 2025.